Page last updated: 2024-12-05

monomethylhydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monomethylhydrazine: Hydrazine substituted by one methyl group. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6061
CHEMBL ID160520
MeSH IDM0014034

Synonyms (56)

Synonym
bdbm50049259
methyl hydrazine
inchi=1/ch6n2/c1-3-2/h3h,2h2,1h
hydrazine, methyl-
methylhydrazine
60-34-4
monomethylhydrazine
brn 0635645
rcra waste no. p068
hsdb 1172
einecs 200-471-4
1-methylhydrazine
monomethyl hydrazine
un1244
rcra waste number p068
MMH ,
methylhydrazine (mono)
ccris 394
ai3-52240
metylohydrazyna [polish]
HDN ,
methylhydrazine, 98%
methyl-hydrazine
CHEMBL160520 ,
methyldiazane
A832701
AKOS005720746
methylhydrazine [un1244] [poison]
uwa30b5z1j ,
ec 200-471-4
metylohydrazyna
unii-uwa30b5z1j
BBL011339
M0558
STL146429
BP-11387
BP-30186
2-methylhydrazine
methylhydrazine [mi]
methylhydrazine [hsdb]
methl hydrazine
n-methyhydrazine
ch3nhnh2
n-methyl hydrazine
menhnh2
2-methyl hydrazine
n-methyl-hydrazine
h2nnhch3
n-methylhydrazine
un 1244
DTXSID4020874 ,
methylhydrazine, purum, >=98.0% (gc)
mfcd00007621
BCP07836
Q417347
20244-39-7

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Several hydrazine derivatives (HD) tested so far have pharmacological activities, but many also have toxic side effects, including carcinogenesis."( Contribution of hydrazines-derived alkyl radicals to cytotoxicity and transformation induced in normal c-myc-overexpressing mouse fibroblasts.
Armelin, MC; Cidade, MR; Gamberini, M; Leite, LC; Valotta, LA, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" In mice exposed to MMH according to a dosing scheme identical to that reported to induce tumours in this species, O6-methylguanine was present in liver and kidney DNA."( Methylation of rat and mouse DNA by the mushroom poison gyromitrin and its metabolite monomethylhydrazine.
Bergman, K; Hellenäs, KE, 1992
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4-aminobutyrate aminotransferase, mitochondrialSus scrofa (pig)Ki2.20000.30001.25002.2000AID73487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4-aminobutyrate aminotransferase, mitochondrialSus scrofa (pig)Kd2.80000.46001.63002.8000AID73484
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID73480Dissociation constant of the Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73493The Reactivation Kinetic Constant for Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73487Inhibitory activity against Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73479Inhibitory rate constant against Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73484The Dissociation Constant for Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-199079 (65.83)18.7374
1990's27 (22.50)18.2507
2000's6 (5.00)29.6817
2010's6 (5.00)24.3611
2020's2 (1.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.98 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.77%)5.53%
Reviews3 (2.31%)6.00%
Case Studies1 (0.77%)4.05%
Observational0 (0.00%)0.25%
Other125 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]